RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2001; 86(01): 08-13
DOI: 10.1055/s-0037-1616195
DOI: 10.1055/s-0037-1616195
Research Article
Protein Z-Dependent Regulation of Coagulation
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
12. Dezember 2017 (online)
Summary
Protein Z (PZ) is a 62 kDa vitamin K-dependent plasma protein that serves as a cofactor for the inhibition of factor Xa by protein Z-dependent protease inhibitor (ZPI). ZPI is a recently identified 72 kDa member of the serpin superfamily of proteinase inhibitors that contains a tyrosine at its reactive center. PZ circulates in plasma in a complex with ZPI. Inhibition of factor Xa by ZPI in the presence of phospholipids and Ca++ is enhanced 1000-fold by PZ, but ZPI also inhibits factor XIa in a process that does not require PZ, phospholipids or Ca++. ZPI activity is consumed during coagulation through proteolysis mediated by factor Xa with PZ and factor XIa. Concomitant PZ deficiency dramatically increases the severity of the prothrombotic phenotype of factor VLeiden mice. Studies to determine the potential roles of PZ and ZPI deficiency in human thrombosis are in progress.
-
References
- 1 Prowse CV, Esnouf MP. The isolation of a new warfarin-sensitive protein from bovine plasma. Biochem Soc Trans 1977; 5: 255-6.
- 2 Broze Jr GJ, Miletich JP. Human protein Z. J Clin Invest 1984; 73: 933-8.
- 3 Fujimaki K, Yamazaki T, Masafumi T, Ichinose A. The gene for human protein Z is localized to chromosome 13 at band q34 and is coded by eight regular exons and one alternative exon. Biochemistry 1998; 37: 6838-46.
- 4 Sejima H, Hayashi T, Deyashiki Y, Nishioka J, Suzuki K. Primary structure of vitamin K-dependent human protein Z. Biochem Biophys Res Commun 1990; 171: 661-8.
- 5 Ichinose A, Takeya H, Espling E, Iwanaga S, Kisiel W, Davie EW. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glyco-protein. Biochem Biophys Res Commun 1990; 172: 1139-44.
- 6 Miletich JP, Broze Jr GJ. Human plasma protein Z antigen: Range in normal subjects and effect of warfarin therapy. Blood 1987; 69: 1580-6.
- 7 Raczkowski CA, Reichlin M, Esmon CT, Comp PC. Protein Z is a negatively responding acute phase protein. Blood. 1987 70 (suppl. 1): 393a (abstr).
- 8 Undar L, Karadogan I, Ozturk F. Plasma protein Z levels inversely correlate with plasma interleukin-6 in patients with acute leukemia and nonHodgkin’s lymphoma. Thromb Res 1999; 94: 131-4.
- 9 Yurdakok M, Gurakan B, Ozbag E, Vigit S, Dundar S, Kirazli S. Plasma protein Z levels in healthy newborn infants. Am J Hematol 1995; 48: 206-7.
- 10 Kemkes-Matthes B, Matthes KJ. Protein Z. Biomed Prog 2000; 13: 51-4.
- 11 Bertolino G, Montani N, Lorezutti F, Balduini CL, Gamba G. Behavior of plasma protein Z levels in patients with abnormal haemostasis: Correlation with coagulation screening times. Thromb Haemost. 1997 78 (suppl 1): 235a (abstr).
- 12 Kemkes-Matthes B, Matthes KJ. Protein Z a new haemostatic factor, in liver disease. Haemostasis 1995; 25: 312-6.
- 13 Bertolino G, Montani N, Anesi E, Palladini G, Capezzera M, Gamba G. Plasma protein Z levels in patients with systemic AL amyloidosis. Thromb Haemost. 1999 suppl.: 136a (abstr).
- 14 Usalan C, Erdem Y, Altun B, Arici M, Haznedaroolu YC, Yasavul U, Turgan C, Caglar S. Protein Z levels in haemodialysis patients. Int Urol Nephrol 1999; 31: 541-5.
- 15 Cobankara V, Ozatly D, Haznedaroolu YC, Buyukapyk Y, Koar A, Kiraz S, Ertenli Y, Dundar S, Kirazly E. Circulating protein Z in reactive and clonal thrombocytosis and in ITP. Thromb Haemost. 1999 suppl.: 563a (abstr).
- 16 Greten J, Kreis I, Liliensiek B, Allenberg J, Amiral J, Ziegler R, Nawroth PP. Localisation of protein Z in vascular lesions of patients with atherosclerosis. Vasa 1998; 27: 144-8.
- 17 McDonald JF, Shah AM, Schwalbe RA, Kisiel W, Dahlback B, Nelsestuen GL. Comparison of naturally occurring vitamin K-dependent proteins: Correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry 1997; 36: 5120-7.
- 18 Hogg P, Stenflo J. Interaction of vitamin K-dependent protein Z with thrombin. J Biol Chem 1990; 266: 10953-8.
- 19 Hogg PJ, Stenflo J. Interaction of human protein Z with thrombin: Evaluation of the species difference in the interaction between bovine and human protein Z and thrombin. Biochem Biophys Res Commun 1991; 178: 801-7.
- 20 Morita T, Kaetsu H, Mizuguchi J, Kawabata S, Iwanaga S. A characteristic property of vitamin K-dependent plasma protein Z. J Biochem 1988; 104: 368-74.
- 21 Kemkes-Matthes B, Matthes KJ. Protein Z deficiency: A new cause of bleeding tendency. Thromb Res 1995; 79: 49-55.
- 22 Subramaniasivam R, Mauron T, Lammle B, Wuillemin WA. Protein Z in healthy human individuals and in patients with a bleeding tendency. Brit J Haematol 1998; 102: 1219-23.
- 23 Gamba G, Bertolino G, Montani N, Spedini P, Balduini CL. Bleeding tendency of unknown origin and protein Z levels. Thromb Res 1998; 90: 291-5.
- 24 Yin Z-F, Huang Z-F, Cui J, Fiehler RW, Lasky N, Ginsburg D, Broze Jr GJ. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci USA 2000; 97: 6734-8.
- 25 Han X, Fiehler R, Broze Jr GJ. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci USA 1998; 95: 9250-5.
- 26 Han X, Huang Z-F, Fiehler R, Broze Jr GJ. The protein Z-dependent protease inhibitor is a serpin. Biochemistry 1999; 38: 11073-8.
- 27 New L, Liu K, Kamali V, Plowman G, Naughton BA, Purchio AF. cDNA cloning of rasp-1, a novel gene encoding a plasma protein associated with liver regeneration. Biochem Biophys Res Commun 1996; 223: 404-12.
- 28 Han X, Fiehler RW, Broze Jr GJ. Characterization of protein Z-dependent protease inhibitor. Blood 2000; 96: 3049-55.
- 29 Danielsson A, Bjork I. Properties of antithrombin-thrombin complex formed in the presence and the absence of heparin. Biochem J 1983; 213: 345-53.
- 30 Bouma BN, Meijers JC. Fibrinolysis and the contact system: a role for factor XI in the down-regulation of fibrinolysis. Thromb Haemost 1999; 82: 243-50.
- 31 Tabatabai A, Fiehler R, Broze Jr GJ. Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thromb Haemost. in press.
- 32 Rezaie AR, Copper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995; 270: 25336-9.
- 33 Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alternation of serpin specificity by a protein cofactor: vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265: 13029-35.
- 34 Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78: 1254-61.
- 35 Naski MC, Lawrence DA, Moshert DF, Podor TJ, Ginsburg D. Kinetics of inactivation of α-thrombin by plasminogen activator inhibitor–1: comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem 1993; 268: 12367-72.
- 36 Fa M, Karolin J, Aleshkov S, Strandberg L, Johansson LB-A, Ny T. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Biochemistry 1995; 34: 13833-40.
- 37 van Meijer M, Smilde A, Tans G, Nesheim ME, Pannekoek H, Horrevoets AJG. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin. Blood 1997; 90: 1874-82.
- 38 van Meijer M, Stoop A, Smilde A, Preissner KT, van Zonneveld A-J, Pannekoek H. The composition of complexes between plasminogen activator inhibitor 1, vitronectin, and either thrombin or tissue-type plasminogen activator. Thromb Haemost 1997; 77: 516-21.
- 39 Eitzman DT, Westrick RJ, Cui J, Yang A, Purkayastha A, Yang T, Tyson J, Christie PD, Rosenberg RD, Ginsburg D. Identification of a strain specific modifier gene for thrombosis in factor V Leiden mice. Blood. 1999 94 (suppl 1): 373a (abstr).
- 40 Huang Z-F, Higuchi D, Lasky N, Broze Jr GJ. Tissue factor pathway inhibitor (TFPI) gene-disruption produces embryonic lethality in mice. Blood 1997; 90: 944-51.
- 41 Jalbert LR, Rosen ED, Moons L, Chan JCY, Carmeliet P, Collen D, Castellino FJ. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998; 102: 1481-8.
- 42 Westrick RJ, Eitzman DT, Cui J, Broze Jr GJ, Ginsburg D. Lethal thrombosis resulting from heterozygous tissue factor pathway inhibitor deficiency in homozygous factor V Leiden mice. Blood. 1999 94 (suppl. 1): 373a (abstr).
- 43 Vasse M, Guegan-Massardier E, Borg J-Y, Woimant F, Soria C. High frequency of protein Z deficiency in patients with ischemic stroke. Lancet. in press.
- 44 Goodnight SH, Griffin JH. Hereditary thrombophilia. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U. eds. Williams Hematology. New York: McGraw-Hill; 2001: 1697-714.
- 45 Nowak-Göttl U, Strater R, Heinecke A, Junker R, Koch H-G, Schuierer G, von Eckardstein A. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999; 94: 3678-82.
- 46 Margaglione M, D’Andrea G, Giuliani N, Brancaccio V, De Lucia D, Grandone E, De Stefano V, Tonali PA, Di Minno G. Inherited prothrombotic conditions and premature ischemic stroke. Arterioscler Thromb Vasc Biol 1999; 19: 1751-6.
- 47 Kemkes-Matthes B, Matzdorff AC, Matthes KJ. Protein Z influences prothrombotic phenotype of factor V Leiden in humans. Blood. 2000 96 (suppl. 1): 534a (abstr).